読み込み中
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
前日終値
$100.6
+$0.12 · +0.12%
日中の時刻はETです。市場データは遅延する場合があります。
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
日中レンジ
現在 $100.6
52週レンジ
現在 $100.6
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
53
適正価値
センチメント
65
強気
リスク
56
やや高いリスク
モメンタム
37
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
日中レンジ
現在 $100.6
52週レンジ
現在 $100.6
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 6.06億 USD | 3.64億 USD | 3.05億 USD | 2.45億 USD | 1.88億 USD |
| 売上原価 | 1.25億 USD | 8574.2万 USD | 6557.3万 USD | 5512.6万 USD | 4415.2万 USD |
| 粗利益 | 4.82億 USD | 2.78億 USD | 2.4億 USD | 1.9億 USD | 1.44億 USD |
| 研究開発 | 7.71億 USD | 5.98億 USD | 5.71億 USD | 3.98億 USD | 2.73億 USD |
| 販売・一般管理 | 7.01億 USD | 4.61億 USD | 3.45億 USD | 2.66億 USD | 2.34億 USD |
| 営業費用 | 16.58億 USD | 11.56億 USD | 9.49億 USD | 6.48億 USD | 5.19億 USD |
| 受取利息 | 6065.6万 USD | 5330.7万 USD | 4213.2万 USD | 1108.1万 USD | 17.4万 USD |
| 支払利息 | 8379.5万 USD | 8491.3万 USD | 8169.4万 USD | 2644.6万 USD | 4047.3万 USD |
| 減価償却費と償却費 | 1645万 USD | 1101.3万 USD | 1057.9万 USD | 1033.1万 USD | 1418.2万 USD |
| 営業利益 | −11.77億 USD | −8.78億 USD | −7.1億 USD | −4.57億 USD | −3.75億 USD |
| 純利益 | −12.77億 USD | −9.14億 USD | −7.5億 USD | −4.82億 USD | −4.35億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2011年3月3日 | 1:10 | — | — |
株式分割 | 2000年7月31日 | 1:4 | — | — |
発効済み 2011年3月3日
1:10
発効済み 2000年7月31日
1:4
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI8.4億0.04%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF3.07億0.32%954億 USD0.05%$235+0.80%
Vanguard Morningstar Small-Cap ETFVB3.04億0.16%1853億 USD0.03%$289.48+0.64%
Vanguard Morningstar Mid-Cap ETFVO2.86億0.13%2264億 USD0.03%$81.14+0.92%
Vanguard Morningstar Growth ETFVUG2.18億0.06%3846億 USD0.03%$91.97+0.72%
Vanguard Morningstar Small-Cap Growth ETFVBK1.74億0.38%447億 USD0.05%$344.74+1.22%
iShares Biotechnology ETFIBB1.68億1.59%108.2億 USD0.44%$206.49+3.00%
iShares Russell Mid-Cap Growth ETFIWP1.21億0.61%200.95億 USD0.23%$143.1+1.56%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Mid-Cap ETFVOVanguard Morningstar Growth ETFVUGVanguard Morningstar Small-Cap Growth ETFVBKiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
